EPO published patent EP3930702A1 for Flamel Ireland Limited, inventors Grassot, Grangeon, and Dubow, covering gamma-hydroxybutyrate compositions designed for improved pharmacokinetic properties when administered with food. The application is classified under A61K 31/197, A61K 9/00, A61P 43/00, and A61K 31/19, with designated states including all major European Economic Area countries.

Pharmaceutical companies developing sodium oxybate or related formulations should review this patent for freedom-to-operate implications. While patent publications do not impose compliance obligations, companies in the GHB therapeutic space should assess whether their products fall within the scope of these claims. No immediate regulatory action is required.